Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study
Authors:
- Ilies BenotmaneIlies Benotmane
- Gabriela Gautier-VargasGGGabriela Gautier-Vargas
- Noëlle CognardNCNoëlle Cognard
- Jérôme OlagneJOJérôme Olagne
- Françoise HeibelFHFrançoise Heibel
- Laura Braun-ParvezLBLaura Braun-Parvez
- Jonas MartzloffJMJonas Martzloff
- Peggy PerrinPPPeggy Perrin
- Romain PszczolinskiRPRomain Pszczolinski
- Bruno MoulinBMBruno Moulin
- Samira Fafi-KremerSFSamira Fafi-Kremer
- Sophie CaillardSCSophie Caillard
Open Access
- 5 July 2022
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (7) , 1107
Abstract
Kidney transplant recipients (KTRs) displays marked inter-individual variations in magnitude of immune responses to anti-SARS-CoV-2 vaccination. The aim of this large single-center study was to identify the predictive factors for serological response to the mRNA-1273 vaccine in KTRs. We also devised a score to optimize prediction with the goal of implementing a personalized vaccination strategy. The study population consisted of 564 KTRs who received at least two doses of the mRNA-1273 vaccine. Anti-RBD IgG titers were quantified one month after each vaccine dose and until six months thereafter. A third dose vaccine was given when the antibody titer after the second dose was p < 0.0001) and the occurrence of a good antibody response (AUC = 0.785, p < 0.0001). Notably, antibody titers declined over time both after the second and third vaccine doses. In summary, a high burden of comorbidities and immunosuppression was correlated with a weaker antibody response. A fourth vaccine dose and/or pre-exposure prophylaxis with monoclonal antibodies should be considered for KTRs who remain unprotected.Keywords
This publication has 31 references indexed in Scilit:
- Occurrence of severe COVID-19 in vaccinated transplant patientsKidney International, 2021
- Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort studyClinical Microbiology and Infection, 2021
- Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccineKidney International, 2021
- Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipientsKidney International, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With BelataceptTransplantation, 2021
- Protection of Healthcare Workers Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) ReinfectionClinical Infectious Diseases, 2021
- An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplantsKidney International, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportNew England Journal of Medicine, 2020
- Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant RecipientsTransplantation, 2020